Michael Aaron Kelly insider trades: Neogenomics (NEO) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 27, 2025 | NEO | ↑ Buy | 5,000 | $7.60 | $38K | M Kelly & B Kelly TTEE Michael and Bonni | May 28, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NEO insiders
Open-market trades in the last 12 months
About Michael Aaron Kelly's insider trades
Michael Aaron Kelly is a director at Neogenomics (NEO). Since May 27, 2025, Michael has reported 1 open-market purchase worth $38K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (34 filings), option exercises (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NEO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.